drugset / Trial / NCT01245608

Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.

NCT01245608 ↗

RandomizedParallel-groupSingle-blindPrevention

Summary

The primary purpose of this study is to determine the effects of a fixed dose combination of valsartan, hydrochlorothiazide, atorvastatin and aspirin (PolyPill) on prevention of cardiovascular events in adults older than 50. Various liver-related variables will also be recorded which will allow studying the effects of PolyPill on the liver and the effect of liver diseases such as nonalcoholic steatohepatitis on cardiovascular events and the protective effect of PolyPill.

Timeline

Start
2011-10
Primary completion
2018-01
Completion
2018-09

Outcome

Missed primary endpoint

paper unadjusted risk ratio (RR) 0.83, 95% confidence interval (CI) 0.66-1.03 PMID 35048107 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 81 mg Oral
Subject Atorvastatin Small molecule 20 mg Oral
Subject Hydrochlorothiazide Unknown 12.5 mg Oral
Subject Valsartan Unknown 40 mg Oral